|
Guselkumab 100 Mg/1 Ml, Injectable Solution, Prefilled Syringe, Human Immunoglobulin 5G, Injectable Solution, Inebilizumab 10 Mg/Ml, 10 Ml Ampoule Vial, Human Plasma Derived C1 Esterase Inhibitor 500 Iu/Ampule Vial, Insulin Degludec 100 Ui/Ml, Applicator Pen With 3 Ml., 04/29/2026 - 21:00:39, Insulin Degludec 100 U/Ml + Liraglutide 3.6 Mg/Ml., Lanreotide 120 Mg Injectable Solution (0.5 Ml Syringe), Mepolizumab 100 Mg/Ml Injectable Solution - Auto Injector Pen (1 Ml), Natalizumab 20 Mg/Ml, 15 Ml Vial, Ocrelizumab 300 Mg/10 Ml, 10 Ml Vial, Octreotide 0.1 Mg/Ml (1 Ml Ampoule), Ofatumumab 20 Mg/0.4 Ml, Prefilled Pen, Omalizumab 150Mg, Prefilled Syringe With 1Ml., Ravulizumab 100 Mg/Ml, Sol Dil Infus Iv Ct Fa Vd Trans Recombinant, 4 Iu, Lyophilic Powder For Injection Solution., Tezepelumab, 210Mg, Applicator Pen Containing 1.91 Ml., Tocilizumab, 20 Mg/Ml, Vial Containing 20 Ml., Ustekinumab 90 Mg, Prefilled Syringe Containing 1 Ml., Vedolizumab, 300 Mg, Powder Lyophilisate For Injectable Solution
|
